All News
Filter News
Found 2,542 articles
-
"Heart Smart for Women: Six S.T.E.P.S. in Six Weeks to Heart-Healthy Living" (Un Corazón Saludable para La Mujer Moderna: Seis P.A.S.O.S. en Seis Semanas para Mantener la Salud del Corazón)
2/14/2019
According to the American Heart Association, cardiovascular disease continues to be the leading cause of death among Latino women.
-
Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
2/12/2019
Interim data show vaccination with mRNA-1653 boosted serum neutralization titers against hMPV and PIV3 at all dose levels tested and was generally well tolerated
-
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
-
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
-
Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial
2/5/2019
Antibody against Chikungunya virus (mRNA-1944) is the first development candidate from Moderna’s systemic therapeutics modalities to start human dosing
-
Messenger RNA (mRNA) is a family of RNA molecules that transport genetic information from DNA to the ribosome, where it specifies the amino acid sequence that creates proteins. In theory, by coding your own mRNA, it should be possible to insert it into the cells and turn them into protein factori...
-
Moderna exercises option for an exclusive product license with Avacta Group plc
2/4/2019
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce that ModernaTX, Inc. has exercised its option to enter into an exclusive licensing agreement with respect to certain Affimers against a potential therapeutic target that has been part of an ongoing research collaboration between the two companies.
-
Alexion Reports Fourth Quarter and Full Year 2018 Results
2/4/2019
4Q18 total revenues of $1,128.8 million, a 24 percent increase over 4Q17 and a 30 percent volume increase
-
Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors
1/30/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that shows the therapeutic potential of mRNA-2752, an investigational mRNA immuno-oncology therapy t
-
Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner
1/18/2019
Moderna, Inc. today announced that John Mendlein, Ph.D., President of Corporate and Product Strategy, will be leaving the Company effective February 1, 2019 to join Flagship Pioneering as an Executive Partner. He will be a strategic consultant to Moderna for six months to ensure a smooth transition.
-
January 11 Research Roundup: Inhalable mRNA, CRISPR and Muscular Dystrophy, Do-It-Yourself DNA De...
1/11/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
-
Moderna’s clinical and business update at the JP Morgan Healthcare Conference led the newly public company shares to pop 4.2 percent, a welcome change.
-
Cygnal Therapeutics Appoints Pearl S. Huang as Chief Executive Officer
1/8/2019
Cygnal Therapeutics today announced the appointment of Pearl S. Huang, Ph.D., as chief executive officer.
-
Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives
1/8/2019
IND amendment submitted to the FDA for a Phase 2 cohort of OX40L (mRNA-2416) to treat advanced ovarian carcinoma
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
-
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference
1/2/2019
Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 37th annual J.P. Morgan Healthcare Conference.